OKYO Pharma Limited (LSE: OKYO) operates as a life sciences and biotechnology company in the United Kingdom. Its development program includes Chemerin for the treatment of ocular inflammation, dry eye disease, and ocular neuropathic pain; and BAM-8, a non-opiod analgesic. OKYO Pharma Limited is headquartered in London, the United Kingdom.

1. 616,287.82
OKYO
Pharma Limited
Proprietary&Confidential©2019OKYOPharmaLimited

2. DISCLAIMER
• This presentation has been prepared by OKYO Pharma Limited (the "Company") solely for your information and for use at a presentation for the purpose of providing background information on the Company,
its business and the industry in which it operates, and has not been approved by the United Kingdom Financial Conduct Authority, London Stock Exchange plc or otherwise. For the purposes of this notice,
"presentation" means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed during the presentation meeting.
• This presentation may not be copied, distributed, reproduced or passed on, directly or indirectly, in whole or in part, or disclosed by any recipient, to any other person (whether within or outside such person's
organisation or firm) or published in whole or in part, for any purpose or under any circumstances.
• The presentation has not been independently verified and no representation or warranty, express or implied, is made or given by or on behalf of the Company or any of its parent or subsidiary undertakings, or
the subsidiary undertakings of any such parent undertakings, or any of such person's respective directors, officers, employees, agents, affiliates or advisers, as to, and no reliance should be placed on, the
accuracy, completeness or fairness of the information or opinions contained in this presentation and no responsibility or liability is assumed by any such persons for any such information or opinions or for any
errors or omissions. All information presented or contained in this presentation is subject to verification, correction, completion and change without notice. In giving this presentation, none of the Company
or any of its parent or subsidiary undertakings, or the subsidiary undertakings of any such parent undertakings, or any of such person's respective directors, officers, employees, agents, affiliates or advisers,
undertakes any obligation to amend, correct or update this presentation or to provide the recipient with access to any further information that may arise in connection with it.
• This presentation does not constitute or form part of, and should not be construed as, any offer, invitation or recommendation to purchase, sell or subscribe for any securities in any jurisdiction and neither the
issue of the information nor anything contained herein shall form the basis of or be relied upon in connection with, or act as an inducement to enter into, any investment activity. This presentation does not
purport to contain all of the information that may be required to evaluate any investment in the Company or any of its securities and should not be relied upon to form the basis of, or be relied on in
connection with, any contract or commitment or investment decision whatsoever. This presentation is not intended to provide complete disclosure upon which an investment decision could be made. The
merit and suitability of an investment in the Company should be independently evaluated and any person considering such an investment in the Company is advised to obtain independent advice as to the
legal, tax, accounting, financial, credit and other related advice prior to making an investment.
• To the extent available, the data contained in this presentation has come from official or third party sources. Third party industry publications, studies and surveys generally state that the data contained
therein have been obtained from sources believed to be reliable, but that there is no guarantee of the accuracy or completeness of such data. While the Company believes that each of these publications,
studies and surveys has been prepared by a reputable source, the Company has not independently verified the data contained therein. In addition, certain of the data contained in this presentation come from
the Company's own internal research and estimates based on the knowledge and experience of the Company's management in the market in which the Company operates. While the Company believes that
such research and estimates are reasonable and reliable, they, and their underlying methodology and assumptions, have not been verified by any independent source for accuracy or completeness and are
subject to change without notice. Accordingly, undue reliance should not be placed on any of the data contained in this presentation.
• This presentation and the information contained herein is not intended for publication or distribution in, and does not constitute an offer of securities in, the United States or to any U.S. person (as defined in
Regulation S under the U.S. Securities Act of 1933 (the "Securities Act"), as amended, Canada, Australia, Japan, the Republic of Ireland, the Republic of South Africa or any other jurisdiction where such
distribution or offer is unlawful. The Company has not registered and does not intend to register the offering in the United States or to conduct a public offering of any securities in the United States.
Securities may not be offered or sold within the United States without registration, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act.
Subject to certain limited exceptions, neither this presentation nor any copy of it may be taken, transmitted or distributed, directly or indirectly, into the United States, its territories or possessions. Any failure
to comply with the foregoing restrictions may constitute a violation of U.S. securities laws. This presentation is only being provided to persons that are (i) “Qualified Institutional Buyers”, as defined in Rule
144A under the Securities Act, or (ii) non-U.S. persons outside the United States, in compliance with Regulation S under the Securities Act. By attending this presentation or by reading the presentation slides,
you warrant and acknowledge that you fall within one of the categories (i) and (ii) above.
• This presentation includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. The words "expect", "anticipate",
"intends", "plan", "estimate", "aim", "forecast", "project" and similar expressions (or their negative) identify certain of these forward-looking statements. These forward-looking statements are statements
regarding the Company's intentions, beliefs or current expectations concerning, among other things, the Company's results of operations, financial condition, liquidity, prospects, growth, strategies and the
industry in which the Company operates, and include statements regarding the Company’s planned pre-clinical studies and clinical trials, regulatory approval process, and demand for our product candidates
are subject to risks, uncertainties, and other factors that could cause actual results to differ materially from those suggested by our forward-looking statements. These factors include, but are not limited to, the
following: we have incurred significant net losses and anticipate that we will continue to incur significant net losses for the foreseeable future; we have never generated any revenue from product sales and
may never be profitable; we will need to raise additional funding in the future, which may not be available on acceptable terms, or at all;; we may not be able to obtain exclusivity or intellectual property rights
for our product candidates or prevent others from developing similar competitive products. The forward-looking statements in this presentation are based on numerous assumptions regarding the Company's
present and future business strategies and the environment in which the Company will operate in the future. Forward-looking statements involve inherent known and unknown risks, uncertainties and
contingencies because they relate to events and depend on circumstances that may or may not occur in the future and may cause the actual results, performance or achievements of the Company to be
materially different from those expressed or implied by such forward-looking statements. Many of these risks and uncertainties relate to factors that are beyond the Company's ability to control or estimate
precisely, such as future market conditions, currency fluctuations, the behaviour of other market participants, the actions of regulators and other factors such as the Company's ability to continue to obtain
financing to meet its liquidity needs, changes in the political, social and regulatory framework in which the Company operates or in economic or technological trends or conditions. Past performance should
not be taken as an indication or guarantee of future results, and no representation or warranty, express or implied, is made regarding future performance. The Company expressly disclaims any obligation or
undertaking to release any updates or revisions to these forward-looking statements to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or
circumstances on which any statement is based after the date of this presentation or to update or to keep current any other information contained in this presentation. Accordingly, undue reliance should not
be placed on the forward-looking statements, which speak only as of the date of this presentation.
• By attending the meeting where this presentation is made or by accepting a copy of this presentation, you agree to be bound by the foregoing limitations and to maintain absolute confidentiality regarding the
information disclosed in this presentation.
Proprietary&Confidential©2019OKYOPharmaLimited

3. INTRODUCTION
• February 2018: the Company entered into a license agreement for Bam-8 with
Tufts Medical Center (patent application PCT/US2016/0611101) for treating
symptoms of neuropathic chronic pain, ocular pain and uveitis associated pain.
• February 2018: the Company obtained a license from On Target Therapeutics
LLC and a sub-license from Tufts Medical Center (patent WO2017014605) for
treating ocular inflammation, dry eye and ocular neuropathic pain with Chemerin
receptor agonist.
• June 2018: the Company finalized the collaboration agreement with On Target
Therapeutics LLC.
• July 2018: the Company hired Raj Patil as Sr. Director of R&D.
• Facilities: Doylestown (Discovery, non-clinical and CMC), London (Finance
team).
Proprietary&Confidential©2019OKYOPharmaLimited

4. G-PROTEIN COUPLED RECEPTOR SIGNALING PLATFORM
 The G-Protein Coupled Receptor (GPCR) signaling field has garnered
worldwide attention from drug developers since a Nobel prize in Chemistry
was awarded in 2012 for research in this area.
 Large pharmaceutical companies such as Novartis, Pfizer & Astra Zeneca are
heavily investing in modulation of GPCR signaling.
 About 30% of all marketed drugs target GPCRs.
 OKYO is focusing on therapeutic applications of two different GPCR targets:
 Chemerin receptor agonist OKYO-0101 for dry eye, uveitis and allergic
conjunctivitis
 MAS-Related GPCR (MRGPR) agonist OKYO-0201 for ocular and chronic
pain
Proprietary&Confidential©2019OKYOPharmaLimited

5. R&D STRATEGY
Chemistry Partner:
Ambiopharm with
API capability from
gram to 100 kg
OKYO-0201: Non-
opioid analgesic
peptide for pain
OKYO-0101: Novel
Chemerin receptor
agonist for dry eye
R&D Focus
Strong IP Portfolio
IP Law firm: Cooley
OKYO key assets
 OKYO-0101: A novel class of membrane-anchored Chemerin receptor GPCR agonist that
inhibits inflammatory pathways, the root cause of dry eye, uveitis and allergic
conjunctivitis.
 OKYO-0201: An agonist for MAS-Related G Protein-Coupled Receptor (MRGPR) that
inhibits neuropathic and inflammatory pain pathways involved in ocular and chronic pain.
Proprietary&Confidential©2019OKYOPharmaLimited

6. INFLAMMATION IS THE MOST COMMON CAUSE OF DYE EYE
Steroidogenesis Inflammation
Chem-9
Chemerin GPCR Signaling Pathway
• Chemerin acts as an agonist for GPR1 (Chem23)
receptor and activates proinflammatory pathways
through GPCR signaling
• Chemerin derived peptides inhibit the inflammatory
responses of active chemerin
• Therefore, Chemerin is an important target in
improving dry eye symptoms

7. EYE DISEASES OF HIGH UNMET NEED
AMD
Glaucoma
Dry Eye
(2017 Revenue $ 3.7 Bln)
DME
Cataract
Allergy
Dry Eye
 Dry Eye is a multifactorial disease caused
by underlying inflammation resulting in the
lack of lubrication and moisture on the
surface of the eye.
 Dry Eye affects over 35% of 50+ older
population, with women representing
approximately two-thirds of those affected.
 Dry eye syndrome represents a major
economic burden in public healthcare
accounting to total annual cost for the
management of disease to US economy
more than $50 billion.
Proprietary&Confidential©2019OKYOPharmaLimited

8. DRY EYE – CURRENT TREATMENT
Proprietary&Confidential©2019OKYOPharmaLimited
Current Prescription Drugs for Dry Eye
Drug Formulation Usual adult
dosage
Monthly Cost Comments Market Position
Cyclosporine
(Restasis,
Allergan)
0.05% 1 drop in
each eye
q12h
$426.70
2017 Revenue:
$ 1.4 Bln
Delayed
response,
takes up to 4
months to
improve
symptoms
First line
therapy
Hydroxypropyl
cellulose
(Lacrisert,
Valeant)
5 mg
inserts
1 insert in
each eye qd
$398.10 Administration is
difficult
Not in common
use
Lifitegrast
(Xiidra, Shire)
5% 1 drop in
each eye
q12h
$426.70
2017 Revenue:
$ 259 Mln
Eye irritation,
change in taste
Catching up
with the
cyclosporine

9. stabilize
+
linker anchor
GPCR
Tethered
peptide
variants
GPCR
ancho
GPCRGPCR
Synthetic
anchored drug
Enhanced Drug-like
Properties
Synthetic
chemistry
STEP 2
Add anchor
STEP 3
Recombinant
screen
STEP 1
Selected
peptide
Endogenous
Annotated
Computational
Natural
MEMBRANE-TETHERED LIGAND TECHNOLOGY
(PEPTIDE TO DRUG)
Using membrane-tethered ligand technology we identified
a 9-amino acid lead peptide (OKYO-0101), which showed
efficacy similar to currently marketed drug cyclosporine in
dry eye mouse model
VehicleOKYO-0101
Proprietary&Confidential©2019OKYOPharmaLimited

10. IDENTIFICATION OF LEAD PEPTIDE
Using membrane-tethered ligand technology licensed from On Target
Therapeutics, a lead compound Chem-9 was identified which showed
efficacy greater than full-length protein.VehicleChemerin
Lead peptide Chem-9 improved the
dry eye symptoms in mice model
GPCRAnchor
Hydrophilic
loop
Peptide

11. TWO LEAD PEPTIDES WERE SELECTED FOR ANIMAL STUDIES
Peptide ID Lipid Linker Peptide sequence
Candidate 2
(Peptide 2)
PCS-33449-PI Palmitic acid γGlu-2X-OEG G-G-y-F-L-P-s-Q-F-a-tic-S
Candidate 3
(Peptide 3)
PCS-33450-PI Palmitic acid γGlu G-G-y-F-L-P-s-Q-F-a-tic-S
• Lead peptides were soluble in PBS at 1 mM
• Both the lead peptides were stable at 37 °C for 7 Days
• Peptide 1 was not selected for animal studies due to insolubility

12. EFFECT OF CHEMERIN ANALOGS ON CORNEAL PERMEABILITY IN DRY
EYE MOUSE MODEL
Dry Eye, no treatment
Dry Eye, after treatment
Lead Peptide Lipid Linker Peptide sequence
Chem9 Palmitic acid PEG-8 G-G-y-F-L-P-s-Q-F-a-tic-S
Typical condition
Navie
DED
Positice control
(CS)
Vehichle
Lead Peptide
Peptide 2
Peptide 3
0
200
400
600
800
1000
1200
1400
1600
ImageAnalysis

13. Poster presentation at the Late-Breaking Session at

14. UVEITIS: AN OPPORTUNITY TO EXPLORE FOR
CHEM9/BAM8
Redness, blurry vision,
pain
Inflammatory response
(Autoimmunity, Infection,
exposure to toxins)
Current treatment
• Corticosteroid eye drops and injection
 Long term use is not desirable
• Immunosuppressive agents
 Requires regular blood tests to monitor side effects
Chem9/Bam8 could provide a safer alternative as an
anti-inflammatory treatment for uveitis
• Uveitis is an inflammatory disease
• It is the third leading cause of blindness worldwide
Healthy eye Uveitis eye

15. STATUS OF R&D PIPELINE
8/20/2020
Lead Optimization Pre-Clinical
IND
Submission
Phase 1
OKYO-0101
OKYO-0201
Ocular Pain
Chronic Pain
Dry Eye; Anticipated IND
submission date: Q3, 2021
Uveitis
Allergic
Conjunctivitis
Proprietary&Confidential©2019OKYOPharmaLimited

16. OKYO-0101 DEVELOPMENT TIMELINES
Pre-Clinical Studies
IND Enabling
Studies
IND
Submission
Lead peptide
identified
GMP peptide
manufacturing
GLP Safety/toxicity
study
Anticipated IND Submission:
Q1, 2021
Animal efficacy and
safety studies
Stability/formulation
studies
ADME/PK studies
Proprietary&Confidential©2019OKYOPharmaLimited
1stDiseaseIndication:DryEye

17. CHRONIC PAIN - GLOBAL PUBLIC HEALTH PRIORITY
 Chronic pain is a health crisis due to its high prevalence. More
than 20% of adults suffer from chronic pain globally.
 Use of opioid medications, such as OxyContin®, Percocet®,
Vicodin® and Percodan®, is the most common therapy in the
management of acute and chronic pain.
 Misuse and overdose of opioid medication has created worldwide
opioid epidemic. The economic impact of opioid crisis is more than
$100 billion per year in US alone.
 Therefore, non-opioid strategies for pain management is an urgent
medical need.
Proprietary&Confidential©2019OKYOPharmaLimited

18.  MAS-Related GPCR (MRGPRs) involved in the perception of pain are
mainly expressed in the sensory neurons.
 Activation of MRGPR by OKYO-0201 agonist inhibits perception of
pain. Therefore, OKYO-0201 has potential to be developed as non-
opioid analgesic for pain.
 OKYO acquired an exclusive worldwide license for OKYO-0201
from Tufts Medical Centre. It is currently being explored for the
following disease indications:
 Ocular pain
 Chronic pain
 In parallel, OKYO is exploring identification of novel MRGPR agonists
to further support it’s use for other inflammatory diseases and expand
IP portfolio.
OKYO-0201: NON-OPIOID ANALGESIC FOR PAIN
Proprietary&Confidential©2019OKYOPharmaLimited

19. OKYO-0201 DEVELOPMENT TIMELINES
Lead peptide
identified
IND enabling studies
Efficacy evaluation in
animal models
Anticipated IND Submission:
TBC
Identification of novel
analogs using cell based
assay
(expected to be completed
by Q2 2019)
Synthesis of
new analogs
Topical formulations
Pre-Clinical Studies
IND Enabling
Studies
IND
Submission
Proprietary&Confidential©2019OKYOPharmaLimited
1stDiseaseIndication:OcularPain

20. NON-OPIOID ANALGESICS FOR PAIN – R&D STRATEGY
 Addiction of opioid medication has created worldwide opioid epidemic.
 Bovine adrenal medulla (BAM8) peptides exhibit potent analgesic
activity. Therefore, BAM8 has potential to be developed as non-opioid
analgesics for pain
 OKYO acquired Bam-8 peptide license from Tufts University. It could
be explored for following disease indications
 Ocular Pain
 Uveitis associated pain
 Neuropathic chronic pain
 In parallel, OKYO is exploring identification of novel Bam8 analogs to
other inflammatory diseases and expand IP portfolio

21. BAM8: AN AGONIST OF MAS-RELATED G PROTEIN-COUPLED
RECEPTOR (MRGPR)
• MRGPRs are expressed mainly in sensory neurons and are involved in the
perception of pain.
• Activation of MRGPR by Bam8 inhibits chronic pain.
Ca
mobilization
ERK/IkB
activation
G protein
Inflammation/Pain

22. LIPIDATED BAM 8 AND G2-MSH PEPTIDES LICENSED FROM TUFTS
UNIVERSITY
Bam 8-22 – VGRPEWWMDYQKRYG
• Lipidated BAM8 – VGRPEWWMDYQKRYGGGK – coupled to palmitic acid via PEG linker
• Claimed two amino acid modifications – M15A and Y17W
• g2-MSH – YVMGHFRWDRFG – coupled to palmitic acid via PEG linker

23. BAM8 - R&D STRATEGY
• Identify novel analogs
• Strengthen IP portfolio
BAM8
Keep same
VGRPEWWMDYQKRYGPalmitic
acid
PEG-8
Amino acid substitutions:
Single
Double
Fluorinated,
Unnatural amino acid
D-amino acids
Truncated Peptide
Cyclized Peptide
N-Methylation
Cell based
assays to
confirm
activity

24. STRONG INTELLECTUAL PROPERTY PORTFOLIO
Family Subject Priority Date Status Country PCT Details
Chemerin
COMPOUNDS AND METHODS FOR TREATING
INFLAMMATION 1/22/2016 Application Filed USA PCT/US2017/014605
COMPOUNDS AND METHODS FOR TREATING
INFLAMMATION 1/22/2016 Application Filed Australia PCT/US2017/014605
COMPOUNDS AND METHODS FOR TREATING
INFLAMMATION 1/22/2016 Application Filed Canada PCT/US2017/014605
COMPOUNDS AND METHODS FOR TREATING
INFLAMMATION 1/22/2016 Published
European
Patent Office
PCT/US2017/014605
COMPOUNDS AND METHODS FOR TREATING
INFLAMMATION 1/22/2016 Application Filed Japan PCT/US2017/014605
Bam-8
COMPOUNDS AND METHODS FOR TREATING PAIN
11/9/2015 Application Filed Canada PCT/US2016/061101
COMPOUNDS AND METHODS FOR TREATING PAIN
11/9/2015 Published
European
Patent Office
PCT/US2016/061101
COMPOUNDS AND METHODS FOR TREATING PAIN
11/9/2015 Published USA PCT/US2016/061101
Soluble Lipidated
Agents
METHODS AND SYSTEMS FOR DESIGNING
AND/OR CHARACTERIZING SOLUBLE LIPIDATED
LIGAND AGENTS
4/12/2013 Allowed USA PCT/US2014/026662
METHODS AND SYSTEMS FOR DESIGNING
AND/OR CHARACTERIZING SOLUBLE LIPIDATED
LIGAND AGENTS
4/12/2013 Allowed USA PCT/US2014/026662
Proprietary&Confidential©2019OKYOPharmaLimited